AstraZeneca Shares Rebound After Bristol Myers Deal Rumors Quashed
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
/ 1648 items
#XY↓
Eli Lilly Raises 2026 Revenue Forecast as GLP-1 Drugs Fuel Record Growth
Eli Lilly beats Q2 estimates with revenue up 48% to $23B, driven by Mounjaro and Zepbound. Company raises full-year outlook to $85–87 billion.
Sight Sciences Stock Jumps After FDA Clears New OMNI Ultra Glaucoma Device
Sight Sciences gets FDA clearance for OMNI Ultra, the first single-pass implant-free MIGS device for glaucoma.
FILSPARI Demand Soars: Travere Posts 96% Sales Growth and Strong FSGS Launch
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
Novo Nordisk’s Guidance Raise Wasn’t Enough: The Lingering Challenges That Drove Shares Lower
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
P&G Buys Thorne for $3.8 Billion to Boost Health and Wellness Business
CEO announces the deal on CNBC.